Eclipse 2000 To Compete Against PLC's Heart Laser In TMR Market
This article was originally published in The Gray Sheet
PLC Medical's Heart Laser 1% perioperative mortality in stable angina patients may be viewed by cardiac surgeons as a significant advantage over the 5% rate for the Eclipse 2000, which was recommended for approval by FDA's Circulatory System Devices Panel at its Oct. 27 meeting. Both lasers are used in transmyocardial revascularization procedures to treat angina.
You may also be interested in...
3D-printing company Carbon and in vitro diagnostics maker Resolution Medical announced plans to manufacture more than one million 3D-printed nasal swabs per week to test for COVID-19. See what Resolution Medical’s president Shawn Patterson said about it here.
FDA warning to "Genesis II Church of Health and Healing " wasn't its first to the organization about promoting a chlorine dioxide formulation, "Miracle Mineral Solution," as an unapproved new drug. 'Infowars' host Alex Jones also was warned about bogus COVID-19 claims.
The first major revision since 2007 notably provides a legal foundation for special approvals under a public health crisis.